Ampicillin
- TRADE NAMES: Amfipen; Ampicin; Binotal; D-Amp; Marcillin; Penbritin; Penstabil; Principen; Pro-Ampi; Sinaplin; Taro-Ampicillin Trihydrate; Totacillin (GSK); Totapen; Vidopen
- INDICATIONS: Susceptible strains of gram-negative and gram-positive bacterial infections
- CLASS: Antibiotic; penicillin
- HALF-LIFE: 1–1.5 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Allopurinol, Anticoagulants, Chloramphenicol, Cyclosporine, Demeclocycline, Doxycycline, Erythromycin, Imipenem/Cilastatin, Levodopa, Methotrexate, Minocycline, Oxytetracycline, Sulfonamides, Tetracycline
PREGNANCY CATEGORY: B
Five to 10% of people taking ampicillin develop eruptions between the 5th and 14th day following initiation of therapy. Also, there is a 95% incidence of exanthematous eruptions in patients who are treated for infectious mononucleosis with ampicillin. The allergenicity of ampicillin appears to be enhanced by allopurinol or by hyperuricemia. Ampicillin is clearly the more allergenic of the two drugs when given alone.
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 06/25/2020
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
